The Infrastructure Insider newsletter provides news and information on the current infrastructure markets, focusing on ...
We thank Yutaka Shimazu for his constructive comments on our HD21 trial.1 In the PET-2 positive cohort, 165 (69%) of 240 patients treated with brentuximab vedotin, etoposide, cyclophosphamide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback